TY - JOUR
T1 - Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021
AU - Rothstein, Tanner E.
AU - Cunningham, Scott A.
AU - Rieke, Rachelle A.
AU - Mainella, Jill M.
AU - Mutchler, Melissa M.
AU - Patel, Robin
N1 - Publisher Copyright:
© 2022 American Society for Microbiology. All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - The epidemiology of macrolide resistance in Mycoplasma (Mycoplasmoides) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
AB - The epidemiology of macrolide resistance in Mycoplasma (Mycoplasmoides) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
KW - Mycoplasma pneumoniae
KW - antibiotic resistance
KW - macrolides
KW - pneumonia
KW - surveillance studies
UR - http://www.scopus.com/inward/record.url?scp=85128448834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128448834&partnerID=8YFLogxK
U2 - 10.1128/aac.02432-21
DO - 10.1128/aac.02432-21
M3 - Article
C2 - 35311520
AN - SCOPUS:85128448834
SN - 0066-4804
VL - 66
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 4
ER -